Atropine Care Ophthalmic and Galantamine
Determining the interaction of Atropine Care Ophthalmic and Galantamine and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using galantamine together with atropine ophthalmic may decrease the benefits of galantamine in the treatment of dementia. Galantamine may also counteract the benefit of atropine ophthalmic. Atropine ophthalmic should generally be avoided in patients with Alzheimer's disease or other cognitive problems. Atropine ophthalmic may also adversely affect elderly patients by producing symptoms ranging from mild thinking impairment to delirium. It is important that you tell your healthcare provider about all other medications that you are using including vitamins and herbs. Do not stop using your medications without talking to your doctor first.
Professional:GENERALLY AVOID: Acetylcholinesterase inhibitors (e.g., donepezil, galantamine, physostigmine, rivastigmine, tacrine) may antagonize the effects of anticholinergic agents and other agents that rely partially on their anticholinergic activity for therapeutic effects (e.g., some antiparkinsonian and antiemetic/antivertigo agents; class IA antiarrhythmics). By inhibiting the metabolism of acetylcholine, more of the neurotransmitter may be available to compete at muscarinic receptors, the site of action of anticholinergic agents. Conversely, anticholinergic agents may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.
MANAGEMENT: Anticholinergic agents should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives. Caution is required, however, since anticholinergic withdrawal may occur. Seizures have been reported following abrupt discontinuation of anticholinergics during acetylcholinesterase inhibitor therapy.
- "Product Information. Reminyl (galantamine)" Janssen Pharmaceuticals, Titusville, NJ.
- "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.
- Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13
- Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32
- "Product Information. Cognex (tacrine)." Parke-Davis, Morris Plains, NJ.
- Edwards KR, O'Connor JT "Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors." J Am Geriatr Soc 50 (2002): 1165-6
- Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7
- Roe CM, Anderson MJ, Spivack B "Use of anticholinergic medications by older adults with dementia." J Am Geriatr Soc 50 (2002): 836-42
- Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH "Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts." Arch Intern Med 163 (2003): 2716-2724
Generic Name: atropine ophthalmic
Brand name: Atropine-1, Isopto Atropine, Atropisol, Ocu-Tropine, Atropine Care, Atrosulf-1, Atropin-Care
Synonyms: Atropine ophthalmic, Atropine (Ophthalmic)
Generic Name: galantamine
Brand name: Razadyne, Razadyne ER, Reminyl
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Atropine Care Ophthalmic-Galantamine Capsules
- Atropine Care Ophthalmic-Galantamine Extended-Release Capsules
- Atropine Care Ophthalmic-Galantamine Hydrobromide
- Atropine Care Ophthalmic-Galantamine Oral Solution
- Atropine Care Ophthalmic-Galantamine Solution
- Atropine Care Ophthalmic-Galantamine Tablets
- Galantamine-Atropine Eye Drops
- Galantamine-Atropine Eye Ointment
- Galantamine-Atropine Eye Ointment Ophthalmic
- Galantamine-Atropine injection
- Galantamine-Atropine Ointment Ophthalmic
- Galantamine-Atropine ophthalmic